Key facts
| Recalling firm | Glaxosmithkline Consumer Healthcare Holdings DBA Haleon |
|---|---|
| Manufacturer | Not disclosed in the FDA record. |
| Brand name | Not disclosed in the FDA record. |
| Product description | Advil Liqui Gels, Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Distributed by: Pfizer, Madison, NJ 07940, UPC 3 0573 0169 49 3 |
| Classification | Class I |
| Recall number | D-0182-2023 |
| Report date | Not disclosed in the FDA record. |
| Status | Terminated |
| Reason for recall | Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back |
What this classification means
A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class I, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Advil Liqui Gels, Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Distributed by: Pfizer, Madison, NJ 07940, UPC 3 0573 0169 49 3 should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Glaxosmithkline Consumer Healthcare Holdings DBA Haleon. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Glaxosmithkline Consumer Healthcare Holdings DBA Haleon should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Glaxosmithkline Consumer Healthcare Holdings DBA Haleon directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon’s FDA history
Argus HQ has recorded 3 total FDA actions tied to Glaxosmithkline Consumer Healthcare Holdings DBA Haleon: 0 warning letters, 3 recalls, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- Has Glaxosmithkline Consumer Healthcare Holdings DBA Haleon had other FDA recalls or enforcement actions?
- Yes. Argus HQ has recorded 3 total FDA actions tied to Glaxosmithkline Consumer Healthcare Holdings DBA Haleon, including 3 recalls and 0 warning letters.
- What is the FDA recall number for this event?
- FDA recall number D-0182-2023.
- What is the current status of this recall?
- Status as recorded by FDA: Terminated.
- Where can I verify this recall directly with FDA?
- The verbatim FDA record is the source of truth for every recall Argus HQ tracks — always confirm against fda.gov before acting.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon- Recall: Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Class I recall: Advil Liqui Gels (minis), Solubilized ibuprofen capsules, 200mg, Pain Reliever F… →
- Recall: Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Class I recall: Advil (ibuprofen) Tablets, 200 mg, packaged as a) 360-count bottles (UPC 3 0573… →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2023). FDA Recall Database: Class I Recall: Advil Liqui Gels, Solubilized ibuprofen capsules, 200mg, Pain… by Glaxosmithkline Consumer Healthcare Holdings DBA Haleon. Digital Empire LLC. Retrieved from https://argushq.ai/recall/glaxosmithkline-consumer-healthcare-holdings-dba-haleon-d-0182-2023-2023-02-01
"FDA Recall Database: Class I Recall: Advil Liqui Gels, Solubilized ibuprofen capsules, 200mg, Pain… by Glaxosmithkline Consumer Healthcare Holdings DBA Haleon." Argus HQ Research, Digital Empire LLC, 2023, argushq.ai/recall/glaxosmithkline-consumer-healthcare-holdings-dba-haleon-d-0182-2023-2023-02-01.
Argus HQ Research. "FDA Recall Database: Class I Recall: Advil Liqui Gels, Solubilized ibuprofen capsules, 200mg, Pain… by Glaxosmithkline Consumer Healthcare Holdings DBA Haleon." Digital Empire LLC. Accessed July 17, 2026. https://argushq.ai/recall/glaxosmithkline-consumer-healthcare-holdings-dba-haleon-d-0182-2023-2023-02-01.
@misc{argushq_argushq_ai_recall_glaxosmithkline_consumer_healthcare_holdings_dba_haleon_d_0182_2023_2023_02_01_2023,
title = {FDA Recall Database: Class I Recall: Advil Liqui Gels, Solubilized ibuprofen capsules, 200mg, Pain… by Glaxosmithkline Consumer Healthcare Holdings DBA Haleon},
author = {{Argus HQ Research}},
year = {2023},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/recall/glaxosmithkline-consumer-healthcare-holdings-dba-haleon-d-0182-2023-2023-02-01},
note = {Accessed: July 17, 2026}
}Source: FDA.gov — Recalls ↗

